Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 August 2024 | Story Martinette Brits | Photo Supplied
Dr Luther van der Mescht
Dr Luther van der Mescht, Senior Lecturer in the Department of Zoology and Entomology.

Ticks that feed on South Africa’s cattle are developing resistance to the only effective pesticides, making them increasingly difficult to control. If this issue is not addressed, the spread of these parasites and their resistance to pesticides could significantly impact farmers' incomes and food security.

According to a study by Dr Luther van der Mescht, Senior Lecturer in the Department of Zoology and Entomology, many tick populations in South Africa are resistant to at least two of the three main types of acaricides (chemical classes) used in the country.

Dr Van der Mescht notes that with around 12 million cattle in South Africa, these ticks not only lower meat and milk production but also carry pathogens that can cause potentially fatal diseases. He estimates that the economic losses from tick-borne diseases and the use of acaricides could reach up to R670 million annually in the cattle industry alone.

He adds that South Africa's agricultural sector is unique due to its dual farming system, which includes both subsistence and commercial farmers, amplifying the impact of ticks. “The country is also home to a wide variety of tick species that transmit numerous pathogens across a diverse range of habitats and climates in which cattle are farmed. Consequently, the effects of ticks and tick-borne diseases in South Africa may be more severe compared to those in developed countries.”

Dr Van der Mescht highlights that ticks are developing resistance primarily due to poor farm management practices, such as underdosing, overdosing, and excessive use of acaricides. “Additionally, insufficient government support in educating farmers and managing resistance exacerbates the problem.”

Managing acaricide resistance

Dr Van der Mescht explains that while ticks will inevitably develop resistance to acaricides, this usually happens much slower if pesticides are used strategically. To slow the development of resistance, several measures can be implemented: 

• Minimise the number of acaricide treatments.
• Assess tick diversity and acaricide resistance at the farm level and monitor it regularly. The study found that acaricide resistance was highly variable across South Africa, likely due to different farm management practices; hence it should be assessed at the farm level.
• Quarantine animals when transferring them to a new farm, ensuring they are free of ticks before releasing them.
• Rotate acaricides from different chemical classes, with a gap of at least two years between applications.

• Government veterinary services should raise awareness about acaricide resistance and provide support, particularly to under-resourced farmers. Establishing acaricide resistance testing laboratories would help monitor resistance and offer guidance to farmers.

Expert in parasitology

Dr Van der Mescht is particularly fascinated by the fact that most animals on earth follow a parasitic way of life. He graduated with a PhD in Conservation Ecology from the Department of Conservation Ecology and Entomology at Stellenbosch University in 2015, focusing on rodent parasites.

Career highlights include receiving the Wilhelm Neitz Memorial Scholarship in Parasitology from the Parasitological Society of Southern Africa (PARSA) for study abroad, and the Blaustein Centre for Scientific Cooperation Postdoctoral Fellowship in 2016 from Ben-Gurion University of the Negev, Israel, to conduct research on the experimental evolution of host specialisation. He also received the Claude Leon Foundation Postdoctoral Fellowship in 2019 to study the cat flea at Stellenbosch University’s Department of Botany and Zoology.

With over four years of experience in the industry at a contract research organisation, he has conducted more than 40 clinical studies for international pharmaceutical companies and published over 50 peer-reviewed scientific articles.

Making research visible, impactful, and relevant to society

Dr Van der Mescht recently published an article for The Conversation and participated in interviews with eNCA, Newzroom Afrika, and Cape Talk to discuss his research. “This effort aligns with the Vision 130 strategy of being a regionally engaged university and supports one of the key pillars of research development at the University of the Free State (UFS), which is to make our research visible, impactful, and relevant to society.”

He also highlighted the significance of popular science, noting that it helps scientists communicate their research to a broader audience, build their professional reputation, enhance their funding opportunities, and improve their research outcomes.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept